Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2024 17:23 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are...
March 05, 2024 17:05 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual...
February 21, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
February 15, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular...
January 30, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through...
December 05, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

Commences initial Phase 3 study with first orally delivered epinephrine prodrug candidateReaffirms topline data anticipated in first quarter 2024 WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) --...
November 10, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
November 06, 2023 16:37 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024Completes...
November 02, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through...
October 31, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...